This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moliterno, D. J. Articles by Hillis, L. D. Search for Related Content PubMed PubMed Citation Articles by Moliterno, D. J. Articles by Hillis, L. D.

Circulation, Vol 88, 935-940, Copyright © 1993 by American Heart Association

ARTICLES

Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction

DJ Moliterno, RA Lange, RS Meidell, JE Willard, CC Leffert, RD Gerard, E Boerwinkle, HH Hobbs and LD Hillis
Department of Internal Medicine (Cardiovascular Division), University of Texas, Southwestern Medical Center, Dallas 75235.

BACKGROUND. In the minutes to days after myocardial infarction, endogenous lysis of an occlusive coronary arterial thrombus occurs in most subjects. Compared with those in whom thrombolysis does not occur, those with antegrade flow in the infarct artery have improved left ventricular performance, less left ventricular dilatation, and improved survival. This study was performed to assess intrinsic hemostasis and fibrinolysis in survivors of myocardial infarction with or without antegrade perfusion of the infarct artery. METHODS AND RESULTS. In 105 survivors of infarction (75 men, 30 women; age, 30 to 80 years) not given thrombolytic therapy, coronary angiography revealed a patent (group 1, n = 52) or occluded (group 2, n = 53) infarct artery. Plasma concentrations of plasminogen, fibrinogen, tissue plasminogen activator activity, infarct artery. Plasma concentrations of plasminogen, fibrinogen, tissue plasminogen activator activity, plasminogen activator inhibitor activity, cholesterol, triglycerides, and lipoproteins, including lipoprotein(a) (Lp[a]), were measured in blood procured 23 +/- 13 (mean +/- SD) months after infarction. Groups 1 and 2 were similar in age, sex, race, cardioactive medications, infarct artery, extent of coronary artery disease, and left ventricular performance. Of the plasma constituents assayed, the groups were similar except that Lp(a) averaged 18.5 +/- 21.7 mg/dL in group 1 and 49.1 +/- 44.8 mg/dL in group 2 (P < .001). This difference was evident in both Caucasian (n = 65) (P = .009) and African American (n = 40) (P = .01) subjects. CONCLUSIONS. Survivors of myocardial infarction who failed to recanalize the infarct artery have higher plasma Lp(a) concentrations than those with a patent infarct artery. Lp(a) may inhibit intrinsic fibrinolysis.

This article has been cited by other articles:

				S.-K. Lin, J.-T. Kao, S.-M. Tsai, L.-Y. Tsai, M.-N. Lin, C.-J. Lai, and W.-L. Zhong Association of Apolipoprotein E Genotypes with Serum Lipid Profiles in a Healthy Population of Taiwan Ann. Clin. Lab. Sci., October 1, 2004; 34(4): 443 - 448. [Abstract] [Full Text] [PDF]

				W. S. Weintraub and S. Sadanandan Percutaneous Coronary Intervention in Stable Patients After Acute Myocardial Infarction Circulation, September 16, 2003; 108(11): 1292 - 1294. [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				P. N. Hopkins, L. L. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2783 - 2792. [Abstract] [Full Text]

				J. H. Stein and R. S. Rosenson Lipoprotein Lp(a) Excess and Coronary Heart Disease Arch Intern Med, June 9, 1997; 157(11): 1170 - 1176. [Abstract] [PDF]

				A. W. Haider, F. Andreotti, G. R. Thompson, C. Kluft, A. Maseri, and G. J. Davies Serum Lipoprotein(a) Level Is Related to Thrombin Generation and Spontaneous Intermittent Coronary Occlusion in Patients With Acute Myocardial Infarction Circulation, November 1, 1996; 94(9): 2072 - 2076. [Abstract] [Full Text]

				G. Jurgens, W. C. Taddei-Peters, P. Koltringer, W. Petek, Q. Chen, J. Greilberger, P. F. Macomber, B. T. Butman, A. G. Stead, and J. H. Ransom Lipoprotein(a) Serum Concentration and Apolipoprotein(a) Phenotype Correlate With Severity and Presence of Ischemic Cerebrovascular Disease Stroke, October 1, 1995; 26(10): 1841 - 1848. [Abstract] [Full Text]

				R. L. Desmarais, I. J. Sarembock, C. R. Ayers, S. M. Vernon, E. R. Powers, and L. W. Gimple Elevated Serum Lipoprotein(a) Is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty Circulation, March 1, 1995; 91(5): 1403 - 1409. [Abstract] [Full Text]

				W. Terres, E. Tatsis, B. Pfalzer, F. U. Beil, U. Beisiegel, and C. W. Hamm Rapid Angiographic Progression of Coronary Artery Disease in Patients With Elevated Lipoprotein(a) Circulation, February 15, 1995; 91(4): 948 - 950. [Abstract] [Full Text]